Research Interests
- Breast, Genitourinary and Gastro intestinal Pathology
- Pathology related to Ayurvedic/herbal medications
- Cytology including Cervical cytology
Research Grants
- National Research Council grant (NRC- grant number 11-100), in 2011 for the study ‘Analysis of the HER 2 neu receptor status, and its correlation with the clinicopathological parameters of gastric carcinoma’. Chief investigator. Completed with a journal publication
- National Research Council grant (NRC-grant number 11-051) in 2011 for the study ‘A study on the prevalence and clinico-pathological characterization of triple negative breast carcinomas and those with basal phenotype’. Chief investigator. Completed, with journal publication under review.
- Department of Public Trustee (Kumi and Heram Bilmoria Trust Fund) for cancer research in 2011 for the studies ‘Histological characterization of triple negative breast cancer in Sri Lanka’ Chief investigator. Completed, with journal publication under review. ‘Androgen receptor status of a Sri Lankan breast carcinoma patient cohort, with clinicopathological association, molecular subtype and survival’ Ongoing
- Sultan Qaboos university research grant in 2009 for the study ‘An ultra structural analysis of the effect of the medicinal herb Polpala (Aerva lanata) on the structure of the urinary tract of rat – Chief investigator. Completed with a journal publication
- National Science Foundation (NSF) grant RG/98/M4 in 1999 for study ‘Study to assess prognostically important features of breast carcinoma in a Sri Lankan population’ – Chief investigator. Completed with a journal publication
- National Science Foundation (NSF) grant RG/2004/TM/02 in 2008 for the study ‘Polpala (Aerva lanata) : its effects on the structure and the function of the urinary tract of rat’ – Co investigator. Completed with a journal publication
- Other outcomes: A National immunohistochemistry laboratory has been set up at the National Hospital of Sri Lanka by the Ministry of Health to provide all women affected with Breast cancer with facilities for immune prognostic markers on a non fee levying basis.
